Tuberculosis Research Section
Sangmi Oh, Ph.D.
Staff Scientist
Contact: For contact information, search the NIH Enterprise Directory.
Major Areas of Research
- Medicinal chemistry for tuberculosis drug discovery
- Design and synthesis of chemical probes for the study of Mycobacterium tuberculosis
- Synthetic approaches for the study of mechanism of action
Program Description
The Tuberculosis Research Section (TBRS) is a multidisciplinary group of research scientists composed of biologists, chemists, and clinical researchers who share a common interest in TB drug discovery. Dr. Sangmi Oh is in charge of the chemistry part of TBRS, focusing on medicinal chemistry for the development of novel antitubercular agents and making diverse chemical probes for an in-depth understanding of bacterial bugs.
Biography
Education
Ph.D., 2010, Chemistry Department, Seoul National University, Korea
M.S., 1997, Chemistry Department, Ewha Womans University, Korea
B.S., 1995, Chemistry Department, Ewha Womans University, Korea
Languages Spoken
KoreanIn 2010, Dr. Oh received her Ph.D. in organic chemistry from Seoul National University, Seoul, South Korea. She later worked as a scientist at the Institut Pasteur Korea (IPK) on the medicinal chemistry team. In 2015, she joined TBRS as a visiting fellow and was appointed as a staff scientist in 2020.
Selected Publications
Yadav VD, Boshoff HI, Trifonov L, Roma JSO, Ioerger TR, Barry CE 3rd, Oh S. Synthesis and Structure-Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents. ACS Med Chem Lett. 2023 Aug 15;14(9):1275-1283.
Finin P, Khan RMN, Oh S, Boshoff HIM, Barry CE 3rd. Chemical approaches to unraveling the biology of mycobacteria. Cell Chem Biol. 2023 May 18;30(5):420-435.
Oh S, Libardo MDJ, Azeeza S, Pauly GT, Roma JSO, Sajid A, Tateishi Y, Duncombe C, Goodwin M, Ioerger TR, Wyatt PG, Ray PC, Gray DW, Boshoff HIM, Barry CE 3rd. Structure-Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4H)-ones as Antitubercular Agents. ACS Infect Dis. 2021 Feb 12;7(2):479-492.
Libardo MDJ, Duncombe CJ, Green SR, Wyatt PG, Thompson S, Ray PC, Ioerger TR, Oh S, Goodwin MB, Boshoff HIM, Barry CE 3rd. Resistance of Mycobacterium tuberculosis to indole 4-carboxamides occurs through alterations in drug metabolism and tryptophan biosynthesis. Cell Chem Biol. 2021 Aug 19;28(8):1180-1191.e20.
Oh S, Trifonov L, Yadav VD, Barry CE 3rd, Boshoff HI. Tuberculosis Drug Discovery: A Decade of Hit Assessment for Defined Targets. Front Cell Infect Microbiol. 2021 Mar 15;11:611304.
Oh S, Park Y, Engelhart CA, Wallach JB, Schnappinger D, Arora K, Manikkam M, Gac B, Wang H, Murgolo N, Olsen DB, Goodwin M, Sutphin M, Weiner DM, Via LE, Boshoff HIM, Barry CE 3rd. Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase. J Med Chem. 2018 Nov 21;61(22):9952-9965.